Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 1998

View Archived Issues

Disappointing results of pilot study of SDZ-PSC-833 + doxorubicin in colorectal cancer

More data reported for ADCON-P; FDA okays pivotal trial

Aphton initiates phase I/II trial of Gonadimmune in prostate cancer patients

Hybridon advances antisense drug to phase II

Another market introduction for Novartis bisphosphonate

Introgen acquires option to license Bak gene from LXR

Cortecs: year-end 1998 highlights

COHERE will track long-term effects of beta-blockade in heart failure

Nobel award brings nitric oxide into the limelight

Novel series of inhibitors of protein farnesyltransferase developed at RPR

New heteroarylsulfonamide derivatives from Knoll with broad clinical application

Stroke patients benefit from treatment with anti-ICAM-1 MAb

Bicyclic inhibitors of protein farnesyltransferase for cancer, restenosis, etc.

Roche presents series of OFQ (ORL1) receptor agonists/antagonists

Immunomodulating thalidomide analogues patented by Gruenenthal

Genset, Pharmacia & Upjohn collaborate in pharmacogenomics research

Abbott will collaborate with Nippon Shinyaku on development of incontinence Rx

U.S. patent covers protegrins and synthetic analogues such as IntraBiotics' IB-367

Fluoroquinolone derivative K-12 inhibits HIV in vitro

Demegen receives patent protection for Peptidyl MIMs in cancer indications

Antibody-based cancer product from AltaRex heading for phase I testing

Access signs more agreements for distribution of amlexanox

Successful completion of human safety trials reported for VIMRx wound-healing agent

AHP and Monsanto agree not to merge

Asahi expects approval of dysuria Rx in near future

CEA-Cide receives orphan drug designation

Treatment recommendations for generalized convulsive status epilepticus emerge from VA study

Rituximab now available in Germany

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...